drugset
drugset / Trial / NCT00833391

Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)

NCT00833391 ↗

Phase 1 Completed 16 enrolled XenoPort, Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate the relative drug concentrations achieved with different formulations of GSK1838262 in healthy volunteers.

Timeline

Start
2009-01
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule — —

Indications

No indication recorded.